<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03490968</url>
  </required_header>
  <id_info>
    <org_study_id>180441</org_study_id>
    <secondary_id>18SFRN33900069</secondary_id>
    <nct_id>NCT03490968</nct_id>
  </id_info>
  <brief_title>The Impact of Branched-Chain Amino Acid Metabolism on Limb Dysfunction in PAD</brief_title>
  <official_title>The Impact of Branched-Chain Amino Acid Metabolism on Limb Dysfunction in PAD (MicroPAD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Test the theory that abnormalities in the large blood vessels that deliver blood to your leg&#xD;
      and the very small blood vessels in your leg's muscles (invisible to the eye) work together&#xD;
      to worsen your leg function and walking.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 22, 2018</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>C3/C5acylcarnitine levels in healthy control subjects.</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>C3/C5acylcarnitine levels in PAD exercise group after 12 weeks</measure>
    <time_frame>Change from baseline to 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>C3/C5 acylcarnitine levels in PAD surgical bypass group</measure>
    <time_frame>Change from baseline to 12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Healthy Subjects</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Peripheral Artery Disease (PAD) with Supervised Exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be referred for supervised exercise therapy. Subjects will have 3 visits per week for 12 weeks. Each visit will include a minimum of 30 to 40 minutes of exercise to improve ambulation with a certified trainer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PAD Subjects Who Undergo Revascularization of the Leg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group of subjects are receiving leg revascularization as part of standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Supervised Exercise</intervention_name>
    <description>Subjects will have 3 visits per week for 12 weeks.</description>
    <arm_group_label>Peripheral Artery Disease (PAD) with Supervised Exercise</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Vascular Assessment</intervention_name>
    <description>Screen: Subjects will undergo a H&amp;P, ankle brachial index, ECG, CBC, CMP, lipid panel, HgA1C, and urinalysis. A urine pregnancy test will be performed on women of childbearing age.&#xD;
Testing Visit 1: MRI, IV in common femoral vein with phlebotomy (60 cc total) before and after sphygmomanometric cuff occlusion of lower limb, 6-minute walk test, 4-meter walk speed test, walking impairment questionnaire, and muscle biopsy.&#xD;
Supervised exercise and leg revascularization patients will return in 12 weeks and have the same study procedures as testing visit 1, plus an ankle brachial index, repeated.</description>
    <arm_group_label>Healthy Subjects</arm_group_label>
    <arm_group_label>PAD Subjects Who Undergo Revascularization of the Leg</arm_group_label>
    <arm_group_label>Peripheral Artery Disease (PAD) with Supervised Exercise</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion/exclusion criteria for Healthy Subjects&#xD;
&#xD;
        Inclusion criteria&#xD;
&#xD;
          -  Male or female, age ≥ 50 years old&#xD;
&#xD;
          -  Non-smoker&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Presence of peripheral artery disease&#xD;
&#xD;
          -  History of a heart attack or stroke&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Active cancer&#xD;
&#xD;
          -  Severe renal disease (CrCl &lt; 60)&#xD;
&#xD;
          -  Severe liver disease&#xD;
&#xD;
          -  Active rheumatological diseases&#xD;
&#xD;
        Inclusion/exclusion criteria for PAD Subjects&#xD;
&#xD;
        Inclusion criteria&#xD;
&#xD;
          -  Male or female, age 50 years or older&#xD;
&#xD;
          -  Atherosclerotic PAD, ABI ≤0.85&#xD;
&#xD;
          -  Willing to comply with protocol, attend follow-up appointments, complete all study&#xD;
             assessments, and provide informed consent&#xD;
&#xD;
          -  For Aim 3, subjects will have Rutherford stage 4 or 5 disease&#xD;
&#xD;
          -  For Aim 3, subjects will be undergoing revascularization as standard of care&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Presence of a femoral, popliteal or tibial aneurysm of the index limb&#xD;
&#xD;
          -  Life expectancy less than 2 years&#xD;
&#xD;
          -  A vascular disease prognosis that includes an anticipated above ankle amputation on&#xD;
             index limb within 4 weeks of index procedure&#xD;
&#xD;
          -  Renal dysfunction defined as MDRD eGFR ≤ 20ml/min/173 m2 at the time of screening&#xD;
&#xD;
          -  Currently on dialysis or history of a renal transplant&#xD;
&#xD;
          -  Cirrhosis or active hepatitis&#xD;
&#xD;
          -  A documented hypercoagulable state&#xD;
&#xD;
          -  Myocardial infarction within 6 months&#xD;
&#xD;
          -  Stroke within 6 months&#xD;
&#xD;
          -  Nonatherosclerotic occlusive disease of the lower extremity&#xD;
&#xD;
          -  Any prior infrainguinal revascularization on index limb&#xD;
&#xD;
          -  Current immunosuppressive medication, chemotherapy or radiation therapy&#xD;
&#xD;
          -  Inability to have an MRI&#xD;
&#xD;
          -  Exercise limitation aside from that due to PAD (i.e. COPD, degenerative joint disease,&#xD;
             etc.)&#xD;
&#xD;
          -  Women who are pregnant&#xD;
&#xD;
          -  Women who are nursing&#xD;
&#xD;
          -  Primary indications for systemic oral anticoagulation for active arterial or venous&#xD;
             thromboembolic disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joshua Beckman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emily Shardelow, BS</last_name>
    <phone>+1 (615) 875-8949</phone>
    <email>emily.m.shardelow@vumc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Shardelow, BS</last_name>
    </contact>
    <investigator>
      <last_name>Joshua Beckman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 30, 2018</study_first_submitted>
  <study_first_submitted_qc>March 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2018</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Joshua Beckman</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

